Abstracts tagged "familial Mediterranean fever and tocilizumab"

Abstract Number: 260 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Is Effective in the Treatment of AA Amyloidosis Secondary to Familial Mediterranean Fever
Huri Ozdogan¹, Serdal Ugurlu², Aysa Hacioglu², Yasaman Adibnia² and Vedat Hamuryudan², ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: AA amyloidosis is the long-term complication of various chronic inflammatory diseases avoidable by the treatment of the underlying disease but with no established treatment…
Abstract Number: 1233 • 2014 ACR/ARHP Annual Meeting
Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever
Huri Ozdogan, Serdal Ugurlu, Aysa Hacioglu, Yasaman Adibnia and Vedat Hamuryudan, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: AA amyloidosis is the major long-term complication of various chronic inflammatory diseases like rheumatoid arthritis, ankylosing spondylitis, FMF and other autoinflammatory syndromes. Treatment of…
Abstract Number: 1207 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience
Sedat Yilmaz¹, Muhammet Cinar², Ismail Simsek¹, Hakan Erdem³ and Salih Pay³, ¹Gulhane School of Medicine, Ankara, Turkey, ²Rheumatology, Gulhane School of Medicine, Ankara, Turkey, ³Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey
Background/Purpose: The most frequent underlying diseases responsible for AA amyloidosis worldwide are rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis, while familial Mediterranean fever (FMF)…
Abstract Number: 747 • 2012 ACR/ARHP Annual Meeting
Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Nicola Stein¹, Matthias Witt², Michael Baeuerle³, Fabian Proft¹, Hendrik Schulze-Koops⁴ and Mathias Gruenke¹, ¹Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ³Division of Rheumatology, Klinikum Nürnberg, Nuernberg, Germany, ⁴University of Munich, Munich, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most prevalent episodic fever syndrome with more than 100.000 affected individuals worldwide. Colchicine is the established first-line therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].